Clinical Trial Update: Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS [Phase 1]

View source ↗

Summary

A Phase Ib study evaluating select drug combinations in lower-risk myelodysplastic syndromes has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Myelodysplastic Syndromes | Phase 1 | Status: TERMINATED